CrushSCI.com
68.9Average days
55Median days
12Fastest days
238Longest days
1,1372025 publications

Paper Review Records

All Paper Review Records

15 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

71 days

Real-World Assessment of Prophylactic Anakinra on Neurotoxicity and Cytokine Release Syndrome after CD19 Chimeric Antigen Receptor T-Cell Therapy in Relapsed and Refractory B-Cell Lymphoma: An Inverse Probability of Treatment Weighting Analysis

Authors
Neela Easton; Mia Andreoli; Herman van Besien; Caitlin Gribbin; Michelle Pasciolla; Anna Alperovich; Mateo Mejia Saldarriaga; Barbara Ma; Nora Chokr; Amer Assal; Joshua Fein; Sebastian Mayer; Alexandra Gomez Arteaga; Daniel Choi; Tsiporah Shore; Christopher S. Hackett; Juliet Barker; Samuel YamshonShow moreShow less
Affiliations
NewYork-Presbyterian/Weill Cornell, Hematology & Medical Oncology, New York, New York; NewYork-Presbyterian/Weill Cornell Medical Center, Medicine, New York, New York; Perlmutter Cancer Center, NYU Langone, New York, New YorkShow moreShow less
Source PDF DOI Publisher page
12 days

T-Cell Lymphoma Associated With CAR-T Cell Therapy: A Bayesian Disproportionality Analysis of a National Database

Authors
Connor FreyShow moreShow less
Affiliations
Department of Medicine, University of British Columbia, Vancouver, British Columbia, CanadaShow moreShow less
Source PDF DOI Publisher page
79 days

Comparative Evaluation of Single-Dose and Split-Dose Melphalan Conditioning Concerning Toxicity Profiles and Engraftment Kinetics: A Propensity Score-Matched Analysis

Authors
Ceren Uzunoğlu Güren; Derya Demirtaş; Ezel Elgün; Tuğçe Bulun; Elif Suyanı; Bilal Aygün; Didar Yanardağ Açık; Fahir Özkalemkaş; Vildan Özkocaman; Asu Fergün Yılmaz; Ayşe Tülin Tuğlular; Işık Atagündüz; Tayfur ToptaşShow moreShow less
Affiliations
Department of Hematology, Marmara University Hospital, Istanbul, Turkey; Department of Hematology, Adana City Training and Research Hospital, Adana, Turkey; Department of Hematology, Bursa Uludağ University, Bursa, Turkey; Department of Hematology, Acibadem Fulya Hospital, Istanbul, TurkeyShow moreShow less
Source PDF DOI Publisher page
48 days

Outcomes and Safety of CAR-T Cell Therapy in B-NHL Patients With Reduced Left Ventricular Ejection Fraction

Authors
Alexandra E. Rojek; Jia Guo; Justin Kline; Satyajit Kosuri; Michael R. Bishop; Jeanne DeCara; Peter A. RiedellShow moreShow less
Affiliations
David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, Illinois; Section of Cardiology, Department of Medicine, University of Chicago, Chicago, IllinoisShow moreShow less
Source PDF DOI Publisher page
75 days

Impact of ASTCT Toxicity Grading System on Outcomes After CAR-T for Mature B-Cell Malignancies

Authors
Marina Gomez-Llobell; Silvia Escribano Serrat; Maria Bromberg; Venkatraman Seshan; Sean Devlin; Sigrun Einarsdottir; Ori Ben Valid; Noa Golan-Aceb; Ronit Marcus; Avichai Simoni; Ofrat Beyar-Katz; Shoshan Perek; Ali Abed Al Wahad; Magdalena Corona; Kai Rejeski; Sandeep S. Raj; Parastoo Dahi; Michael Scordo; Gunjan L. Shah; M. Lia Palomba; Gilles Salles; Jae H. Park; Roni Shouval; Abraham Avigdor; Jaime Sanz; Miguel-Angel PeralesShow moreShow less
Affiliations
Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Department of Medicine, Complutense University of Madrid, Madrid, Spain; Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York; Department of Medicine, Weill Cornell Medical College, New York, New York; Hematology and Bone Marrow Transplantation, Sheba Medical Center, Ramat Gan, Israel; Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel; Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; Institute of Hematology, Lady Davis Carmel Medical Center, Haifa, Israel; Department of Medicine III – Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany; Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York; Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York; Hematology Department, Hospital Universitari i Politècnic La Fe, Departament de Medicina Universitat de Valencia, CIBERONC, Instituto Carlos III, SpainShow moreShow less
Source PDF DOI Publisher page
55 days

Vaccine-Induced Anti-HBs Response is Associated with Protection Against Hepatitis B Virus Reactivation after Allogeneic Hematopoietic Cell Transplantation: A Randomized Trial

Authors
Masahiro Onozawa; Shigeru Kusumoto; Yachiyo Kuwatsuka; Takayoshi Miyazono; Masatsugu Tanaka; Yuho Najima; Kohei Okada; Souichi Shiratori; Takayuki Sato; Junya Kanda; Yuichiro Inagaki; Tohru Murayama; Kaoru Hatano; Koichi Onodera; Masatoshi Sakurai; Shinya Endo; Takahiro Kumode; Hidehiro Itonaga; Yukiyoshi Moriuchi; Nobuhiro Kanemura; Tatsuya Imi; Taro Edahiro; Nobuaki Fukushima; Masahiro Oura; Shunsuke Yui; Mitsumasa Watanabe; Tomomi Toubai; Toshihiko Ando; Daisuke Nakamura; Masaharu Tamaki; Yasutaka Kakinoki; Takahiro Okada; Nobuaki Nakano; Takayoshi Tachibana; Hiroaki Shimizu; Shuichi Ota; Shinsuke Iida; Masaya Sugiyama; Yoshiko Atsuta; Takanori Teshima; Tomoharu Yoshizumi; Masashi MizokamiShow moreShow less
Affiliations
Department of Hematology, Hokkaido University Hospital, Sapporo, Japan; Department of Hematology and Cell therapy, Aichi Cancer Center, Nagoya, Japan; Department of Hematology and Oncology, Nagoya City University Hospital, Nagoya, Japan; Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan; Department of Hematology, Imamura General Hospital, Kagoshima, Japan; Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan; Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan; Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan; Department of Hematology, Graduate School of Medicine, Kyoto University Hospital, Kyoto, Japan; Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan; Department of Hematology, Hyogo Cancer Center, Akashi, Japan; Department of Medicine, Division of Hematology, Jichi Medical University, Shimotsuke, Japan; Department of Hematology, Tohoku University Hospital, Sendai, Japan; Department of Medicine, Division of Hematology, Keio University School of Medicine, Tokyo, Japan; Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan; Hematology and Rheumatology, Kindai University, Osaka, Japan; Transfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, Japan; Department of Hematology, Sasebo City General Hospital, Sasebo, Japan; Department of Hematology & Infectious Disease, Gifu University Hospital Gifu, Japan; Department of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, Kanazawa, Japan; Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan; Department of Hematology and Oncology, Konan Kosei Hospital, Konan, Japan; Department of Hematology, Endocrinology and Metabolism, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan; Department of Hematology, Nippon Medical School, Tokyo, Japan; Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan; Department of Hematology and Cell Therapy, Yamagata University Hospital, Yamagata, Japan; Department of Internal Medicine, Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine, Saga University, Saga, Japan; Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan; Department of Hematology, Asahikawa City Hospital, Asahikawa, Japan; Department of Hematology, Shimane University Hospital, Izumo, Japan; Department of Viral Pathogenesis and Controls, National Institute of Global Health and Medicine, Japan Institute for Health Security, Kohnodai, Japan; Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan; Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Genome Medical Sciences Project, National Institute of Global Health and Medicine, Japan Institute for Health Security, Konodai, Japan; Molecular and Cellular Glycoproteomics Research Group, Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tsukuba, JapanShow moreShow less
Source PDF DOI Publisher page

FAQ

How long does Transplantation and Cellular Therapy take to review a manuscript?

As of 2026-11-13, CrushSCI has 15 complete review records for Transplantation and Cellular Therapy. The fastest paper went from submission to acceptance in 12 days (T-Cell Lymphoma Associated With CAR-T Cell Therapy: A Bayesian Disproportionality Analysis of a National Database, received 2026-05-28, accepted 2026-06-09); the slowest took 238 days. The average is 68.9 days and the median is 55 days.

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.